Last reviewed · How we verify
NCT03419130
Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer
Phase 2 trial testing Hypofractionated Radiation Therapy in Infiltrating Bladder Urothelial Carcinoma. Withdrawn.
31 December 2020
Quick facts
| Lead sponsor | University of California, San Francisco |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 18 July 2018 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Hypofractionated Radiation Therapy — full drug profile →
- Laboratory Biomarker Analysis — full drug profile →
- Pembrolizumab (pembrolizumab) — full drug profile →
- Radiation Therapy — full drug profile →
Conditions studied
- Infiltrating Bladder Urothelial Carcinoma — all drugs for Infiltrating Bladder Urothelial Carcinoma →
- Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 — all drugs for Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 →
- Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 — all drugs for Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 →
Sponsor
University of California, San Francisco
Who can join
18 and older, any sex, with Infiltrating Bladder Urothelial Carcinoma or Stage II Bladder Urothelial Carcinoma AJCC v6 and v7. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized phase II trial studies how well radiation therapy and pembrolizumab work in treating patients with urothelial bladder cancer that is restricted to the site of origin, without evidence of spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving radiation therapy and pembrolizumab may work better in treating urothelial bladder cancer.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Radiotherapy as a New Player in Immuno-Oncology.
Wang SJ, Haffty B. · · 2018 · cited 19× · PMID 30558196 · DOI 10.3390/cancers10120515 -
Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations.
Lei H, Shi M, Xu H, Bai S, et al · · 2021 · cited 9× · PMID 33658847 · DOI 10.2147/cmar.s288337
Verify or expand the search:
- PubMed search for NCT03419130
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hypofractionated Radiation Therapy
Trials testing the same drug.
- NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
- NCT07188532 — Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial · NA · recruiting
- NCT07097142 — Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemothera · Phase 3 · recruiting
- NCT06794125 — An Evaluation of Dose-escalation for Intrathoracic Tumours · NA · recruiting
- NCT07052669 — Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC · Phase 3 · recruiting
Other recruiting trials for Infiltrating Bladder Urothelial Carcinoma
Currently open trials in the same condition.
- NCT03609216 — Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Gene · Phase 2 · active not recruiting
Other University of California, San Francisco trials
Trials by the same sponsor.
- NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
- NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
- NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
- NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
- NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03419130 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
- Last refreshed: 7 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03419130.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing